EMAIL THIS PAGE TO A FRIEND

Molecular therapy : the journal of the American Society of Gene Therapy

Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.


PMID 24895995

Abstract

Glioblastoma is a devastating disease, and there is an urgent need to develop novel therapies, such as oncolytic HSV1 (OV) to effectively target tumor cells. OV therapy depends on tumor-specific replication leading to destruction of neoplastic tissues. Host responses that curtail virus replication limit its efficacy in vivo. We have previously shown that cysteine-rich 61 protein (CCN1) activates a type 1 IFN antiviral defense response in glioblastoma cells. Incorporating TCGA data, we found CCN1 expression to be a negative prognostic factor for glioblastoma patients. Based on this, we used neutralizing antibodies against CCN1 to investigate its effect on OV therapy. Use of an anti-CCN1 antibody in mice bearing glioblastomas treated with OV led to enhanced virus expression along with reduced immune cell infiltration. OV-induced CCN1 increases macrophage migration toward infected glioblastoma cells by directly binding macrophages and also by enhancing the proinflammatory activation of macrophages inducing MCP-1 expression in glioblastoma cells. Activation of macrophages by CCN1 also increases viral clearance. Neutralization of integrin αMβ2 reversed CCN1-induced macrophage activation and migration, and reduced MCP-1 expression by glioblastoma cells. Our findings reveal that CCN1 plays a novel role in pathogen clearance; increasing macrophage infiltration and activation resulting in increased virus clearance in tumors.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1405570
Anti-CCNA2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV03045
Anti-CCNA2 antibody produced in rabbit, IgG fraction of antiserum
HPA020626
Anti-CCNA2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2106206
Anti-CCNA2 antibody produced in rabbit, affinity isolated antibody
HPA029853 Anti-CYR61 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2502167
Anti-MPO antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA021147
Anti-MPO antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2101863
Anti-PPP3CA (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2101864
Anti-PPP3CA (ab2) antibody produced in rabbit, affinity isolated antibody
HPA012778
Anti-PPP3CA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SRP3024 CYR61 human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC), cell culture tested
SAB1409321
Monoclonal Anti-MPO antibody produced in mouse, clone 3E11, purified immunoglobulin, buffered aqueous solution
WH0005530M3
Monoclonal Anti-PPP3CA antibody produced in mouse, clone 2G8, purified immunoglobulin, buffered aqueous solution